Measuring tumor hypoxia with 18F-FETNIM PET in esophageal squamous cell carcinoma: A pilot clinical study

Diseases of the Esophagus

Volumn 25, Issue 1, 2012, Pages 54-61

  Yue, J ^a,b   Yang, Y ^a   Cabrera, A R ^c   Sun, X ^b   Zhao, S ^b   Xie, P ^b   Zheng, J ^b   Ma, L ^b   Fu, Z ^b   Yu, J ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

18F fluoromisonidazole PET; Clinical response; Esophageal cancer; Hypoxia

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE; FLUOROURACIL; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HEART; HUMAN; HYPOXIA; LUNG; MALE; MUSCLE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANOXIA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NITROIMIDAZOLES; OXYGEN; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; TREATMENT OUTCOME;

EID: 84855769842     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01209.x     Document Type: Article

References (21)

1. Cooper J S, Guo M D, Herskovic A etal. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-7.
2. Minsky B D, Pajak T, Ginsberg R J etal. INT 0123 (RTOG 94-05) Phase III trial of combined modality therapy for esophageal cancer: high dose (64.8Gy) vs. standard dose (50.4Gy) radiation therapy. J Clin Oncol 2004; 22: 45-52.
3. Gray L H, Conger A D, Ebert M, Hornsey S, Scott O C. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
4. Tzao C, Lee S C, Tung H J etal. Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers 2008; 25: 141-8.
5. Chen Y, Lu Y, Lu C, Zhang L. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. Pathol Oncol Res 2009; 15: 487-93.
6. Tanaka N, Kato H, Inose T etal. Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2008; 99: 1468-75.
7. Koh W J, Rasey J S, Evans M L etal. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212.
8. Yang D J, Wallace S, Cherif A etal. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194: 795-800.
9. Grönroos T, Bentzen L, Marjamäki P etal. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 513-20.
10. Grönroos T, Eskola O, Lehtiö K etal. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 2001; 42: 1397-404.
11. Lehtiö K, Eskola O, Viljanen T etal. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59: 971-82.
12. Zou K H, Warfield S K, Bharatha A etal. Statistical validation of image segmentation quality based on a spatial overlap index. Acad Radiol 2004; 11: 178-89.
13. Vaupel P, Kallinowski F, Okunieff P. Blood perfusion and microenvironment of human tumors. Cancer Res 1989; 49: 6449-65.
14. Kaanders J H, Bussink J, van der Kogel A J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3: 728-37.
15. Lehtiö K, Oikonen V, Grönroos T etal. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. J Nucl Med 2001; 42: 1643-52.
16. Li L, Hu M, Zhu H, Zhao W, Yang G, Yu J Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer 2010; 11: 335-40.
17. Minn H, Grönroos T J, Komar G etal. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des 2008; 14: 2932-42.
18. Sloof G W. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET. Best Pract Res Clin Gastroenterol 2006; 20: 941-57.
19. Schneider P M, Metzger R, Schaefer H etal. Response-evaluation by endoscopy, re-biopsy, and endoscopic ultrasound does not accurately predict histopathologic regression following neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008; 248: 902-8.
20. Stahl M, Stuschke M, Lehmann N etal. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-17.
21. Bedenne L, Michel P, Bouché O etal. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-68.